Sandoz Says Biopharma Biz Added 'Poison' To Market
By Carla Baranauckas · April 29, 2024, 10:00 PM EDT
More than $160 million separate generic-drug maker Sandoz Inc. and biopharmaceutical firm United Therapeutics Corp. in their estimates of damages suffered by Sandoz when the other company effectively blocked the sale...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login